Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients (opens in a new tab)

news-medical.net · 2026-10-23

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

    Nature Medicine · 2026

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Nature Medicine

Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 8Not checkedAn investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 8Not checkedThe findings, published in Nature Medicine, will help researchers design a larger phase 3 clinical trial.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 8Not checkedNearly every patient evaluated after receiving the vaccine developed an immune response against mutated KRAS, and patients with stronger immune responses tended to remain free of disease longer.View evidenceHide evidence

As statednearly every patient evaluated; 98.9% of evaluable vaccinated patients; more than 8 in 10 had a response more than 9 times greater than before vaccination

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 8Not checkedThe study included 144 patients with stage 1-3 KRAS-mutated pancreatic cancer who had undergone surgery and chemotherapy and had no cancer visible on imaging when they entered the trial; 96 were assigned to the vaccine and 48 to observation.View evidenceHide evidence

As stated144 patients; 96 vaccine, 48 observation

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 8Not checkedThe trial did not meet its primary goal of showing an improvement in disease-free survival across the full study population, and the median disease-free survival difference was not statistically significant.View evidenceHide evidence

As stated23.8 months vs 21.2 months

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 6 of 8Not checkedIn exploratory and planned analyses, patients with stronger KRAS-specific T-cell responses, those without detectable ctDNA at baseline, and some patients who had not previously received radiation showed signals of longer disease-free survival with the vaccine.View evidenceHide evidence

As statedmore than 9 times greater; 95.5% still had detectable KRAS-specific T-cell response at 46 weeks

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 7 of 8Not checkedResearchers also reported that the vaccine activated CD4 and CD8 T cells, produced responses against several KRAS mutations, and in a small group of patients appeared to trigger antigen spreading.View evidenceHide evidence

As statedsmall group of patients

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 8 of 8Not checkedOverall survival results are not yet available, and researchers say longer follow-up and a larger study are needed.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Nature Medicine · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 41 candidate papers

Selected

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Nature Medicine · 2026 · Crossref

Source (opens in a new tab)

And 35 more candidates considered.